Phase I/Clinical Pharmacology: Exploratory and Regulatory Driven-Studies
Comprehensive Phase I clinical pharmacology studies by Quotient Sciences help clients by delivering the insights they need in a safe and fast way.
We provide comprehensive clinical pharmacology services for exploratory and regulatory-driven studies. Our end-to-end solutions include expert clinical study design, thorough data analysis, and detailed reporting.
Our fully integrated approach ensures seamless execution of clinical programmes and delivers high-quality clinical results.
Our wide range of clinical pharmacology studies can be run individually or as part of a package to streamline your clinical testing. Integrated services, such as bioanalysis, PK, and data sciences, facilitate rapid data turnaround and reporting.
Our clinical study types
- 14C human ADME/mass balance
- Drug-drug interaction (DDI)
- Food effect (FE)
- TQT/Cardiac safety
- Bioavailability/absolute bioavailability (BA)
- Bioequivalence/biosimilars (BE)
- 14C microdose/microtracer
- Ethnobridging
Quotient Sciences employs a dedicated volunteer management team in the US and the UK that can promptly track and recruit healthy volunteers and special populations, such as healthy smokers, healthy elderly, high BMI, or post-menopausal women, for our clients’ Phase I study.
Our experienced project management and medical staff run programmes guided by scientific and regulatory support. We help customers align their clinical studies with their target while also considering patient safety.
